NASDAQ:ISPC - Nasdaq - US45032V2079 - Common Stock - Currency: USD
NASDAQ:ISPC (2/21/2025, 11:32:40 AM)
1.75
-0.06 (-3.31%)
The current stock price of ISPC is 1.75 USD. In the past month the price decreased by -20.96%. In the past year, price decreased by -80.54%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
VEEV | VEEVA SYSTEMS INC-CLASS A | 36.28 | 36.81B | ||
DOCS | DOXIMITY INC-CLASS A | 57.05 | 13.70B | ||
WAY | WAYSTAR HOLDING CORP | N/A | 7.27B | ||
CERT | CERTARA INC | 33.94 | 2.13B | ||
TDOC | TELADOC HEALTH INC | N/A | 2.05B | ||
GDRX | GOODRX HOLDINGS INC-CLASS A | 15.06 | 1.84B | ||
SDGR | SCHRODINGER INC | N/A | 1.67B | ||
PHR | PHREESIA INC | N/A | 1.66B | ||
EVH | EVOLENT HEALTH INC - A | 16.67 | 1.28B | ||
HSTM | HEALTHSTREAM INC | 50.63 | 1.00B | ||
LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 969.28M | ||
DH | DEFINITIVE HEALTHCARE CORP | 14.85 | 782.65M |
iSpecimen Inc is a US-based company operating in Health Care Technology industry. The company is headquartered in Lexington, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2021-06-17. iSpecimen Inc. is a technology-driven company. The firm's iSpecimen Marketplace platform is designed to transform the biospecimen procurement process to accelerate medical discovery. The firm's technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. Its iSpecimen Marketplace platform has compiled de-identified healthcare data provided by its healthcare supply partners. The platform is built upon a robust healthcare data set comprised of information about available specimens and research subjects. The Company’s platform helps with administrative and reporting functions for researchers, suppliers, and its internal personnel, including user and compliance management. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data, administrative, compliance and reporting.
ISPECIMEN INC
450 Bedford St Ste 1010
Lexington MASSACHUSETTS US
CEO: Christopher Ianelli
Employees: 53
Company Website: http://www.ispecimen.com/
Investor Relations: https://ispecimen.irpass.com/
Phone: 17813016700
The current stock price of ISPC is 1.75 USD. The price decreased by -3.31% in the last trading session.
The exchange symbol of ISPECIMEN INC is ISPC and it is listed on the Nasdaq exchange.
ISPC stock is listed on the Nasdaq exchange.
ISPECIMEN INC (ISPC) has a market capitalization of 1.68M USD. This makes ISPC a Nano Cap stock.
ISPECIMEN INC (ISPC) currently has 53 employees.
ISPECIMEN INC (ISPC) has a resistance level at 1.89. Check the full technical report for a detailed analysis of ISPC support and resistance levels.
The Revenue of ISPECIMEN INC (ISPC) is expected to grow by 6.58% in the next year. Check the estimates tab for more information on the ISPC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ISPC does not pay a dividend.
ISPECIMEN INC (ISPC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.7).
The outstanding short interest for ISPECIMEN INC (ISPC) is 4.73% of its float. Check the ownership tab for more information on the ISPC short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ISPC. The financial health of ISPC is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ISPC reported a non-GAAP Earnings per Share(EPS) of -18.7. The EPS increased by 17.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -84.55% | ||
ROE | -202.01% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ISPC. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 96.29% and a revenue growth 6.58% for ISPC